Background/aims: The role of high mobility group box chromosomal protein 1 in hepatocellular carcinoma is unknown. The aim of study was to evaluate contributions of high mobility group box chromosomal protein 1 in hepatocellular carcinoma, and analyse the correlation between high mobility group box chromosomal protein 1 and clinicopathologic outcomes VSports手机版. .

Patients/methods: High mobility group box chromosomal protein 1 levels were analysed by Western blot analysis. Edmondson grade, TNM stage and the Cancer of the Liver Italian Program score were used as analysis variables V体育安卓版. .

Results: The serum high mobility group box chromosomal protein 1 levels in hepatocellular carcinoma (84. 2 +/- 50. 4 ng/ml) was significantly higher than those in chronic hepatitis (39. 8 +/- 10. 5 ng/ml), liver cirrhosis (40. 2 +/- 11. 6 ng/ml) and healthy control (7. 0 +/- 5. 9 ng/ml, p < 0. 0001, respectively), and positive correlation were found between high mobility group box chromosomal protein 1 and alpha-fetoprotein (r = 0. 952, p < 0 V体育ios版. 0001), and between high mobility group box chromosomal protein 1 and the size of tumour (r = 0. 904, p < 0. 0001). High mobility group box chromosomal protein 1 were significant differences among Edmondson grade I, II, III, IV; TNM stage I, II, III, IV and Cancer of the Liver Italian Program score 0-1 points, 2-4 points, > 4 points (p < 0. 0001, respectively). .

Conclusions: These results suggest that high mobility group box chromosomal protein 1 may be a useful marker for evaluating the tumour stage and predicting prognosis in hepatocellular carcinoma. Targeting high mobility group box chromosomal protein 1 production or release might have potential approaches for hepatocellular carcinoma treatment. VSports最新版本.